iXensor Confirms PixoTest® COVID-19 Antigen Test Detects Omicron and Other Key Variants of Concern


News and research before you hear about it on CNBC et al. Claim your 1-week free trial for Street Insider Premium here.


TAIPEI, Taiwan – (BUSINESS WIRE) – iXensor Co., Ltd. (6734.TWO)

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211222005223/en/

IXensor’s PixoTest COVID-19 Antigen Test Effectively Detects Omicron and Other Key Variants of Concern (Photo: Business Wire)

Mobile Health Pioneer iXensor Says Its Computer Vision-Based PixoTest® COVID-19 Antigen Test Effectively Detects All Major Variants of SARS-CoV-2, Including Omicron (B.1.1.529) after completing two validation studies.

In response to new emerging waves of the COVID-19 pandemic caused by Omicron across the world, iXensor performed in silico analysis followed by laboratory validation using the recombinant protein of the Omicron variant. The in-silico study evaluated the amino acid sequences of the wild-type N protein and the Omicron variant (P13L, E31del, R32del, S33del, R203K, G204R), concluding that Omicron is detectable by PixoTest® COVID -19 Antigen Test. In addition, in the study on recombinant proteins, PixoTest® achieved the same detection limit (0.25 ng / ml) on these worrisome variants as on the original wild type of SARS-CoV-2 used as a control.

Both study results affirm that the PixoTest® COVID-19 Antigen Test can effectively detect the latest variant of Omicron in addition to the previous confirmation on SARS-CoV-2 Alpha (B.1.1.7), Beta ( B.1.351), Gamma (P.1), Delta (B.1.617.2). More importantly, the sensitivity of the PixoTest® COVID-19 Antigen Test is not affected by the Omicron and other variants of concern.

Although vaccines have become widely available, Omicron is more likely to cause breakthrough infections and fundamentally change the pandemic landscape around the world. Rapid tests that cannot detect the Omicron variant are a worrying prospect, as false negative results could potentially lull people into a false sense of security.

IXensor CEO Dr Carson Chen commented, “Now more than ever, frequent testing detectable by Omicron remains a critical part of the COVID-19 response to keep communities open, employees and students safe, and allow people to resume their travels with less fear. . ”

About iXensor

iXensor, the pioneer in mobile health, transforms smartphones into laboratory-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world’s first FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into home self-testing and point-of-care clinical diagnosis of infectious diseases, women’s health, diabetes, diabetes and cardiovascular disease.

Media contact

Spokesperson: Patrick Liao

Website: www.ixensor.com

Email: [email protected]

Phone: + 886-928-570-208

Source: iXensor Co., Ltd.

Source link

About Nereida Nystrom

Check Also

Beam Therapeutics reports progress on Ex Vivo and In

First subject scheduled to be enrolled in the BEAM-101 phase 1/2 clinical trial for the …